Oct 21, 2025 07:00AM
Oct 9, 2025 06:02AM
Oct 9, 2025 06:01AM
Jun 13, 2025 11:43AM
May 13, 2025 04:52AM
May 5, 2025 09:51AM
Mar 24, 2025 09:13AM Notice to Long-Term Shareholders of Akero Therapeutics, Inc. (Nasdaq: AKRO); Driven Brands Holdings, Inc. (Nasdaq: DRVN); Integra Lifesciences Holdings Corporation (Nasdaq: IART); and Kyverna Therapeu
Jan 28, 2025 05:02AM
Dec 19, 2024 02:00PM
Oct 20, 2024 10:00AM
Aug 1, 2024 08:00AM
Jun 5, 2024 04:18PM
May 16, 2024 04:15PM
May 7, 2024 03:06PM AKRO Class Action Alert: Robbins LLP Reminds Investors of the Lead Plaintiff Deadline in the Class Action Against Akero Therapeutics, Inc.
May 2, 2024 01:30PM
Apr 30, 2024 12:42AM
Apr 22, 2024 06:11AM
Feb 29, 2024 07:00AM
Dec 18, 2023 07:00AM
Nov 13, 2023 07:00AM
May 15, 2023 07:00AM Akero Therapeutics Reports First Quarter 2023 Financial Results and Provides Business Update
Mar 29, 2023 04:01PM
Mar 29, 2023 04:01PM
Mar 29, 2023 04:01PM
Dec 21, 2022 04:01PM
Dec 21, 2022 04:01PM
Dec 19, 2022 10:36AM
Dec 8, 2022 07:02AM Akero Therapeutics (AKRO) Announces Efruxifermin Granted FDA Breakthrough Therapy Designation for NASH
Dec 8, 2022 07:00AM
Dec 8, 2022 07:00AM
Nov 15, 2021 06:14AM
Nov 12, 2021 08:01AM
Nov 12, 2021 08:01AM
Nov 12, 2021 08:01AM
Nov 12, 2021 07:00AM Akero Therapeutics Reports Third Quarter 2021 Financial Results and Provides Business Update
Nov 12, 2021 07:00AM
Oct 20, 2021 09:27AM
Oct 19, 2021 06:04PM
Oct 19, 2021 04:15PM
Oct 19, 2021 04:15PM
Oct 19, 2021 04:15PM
Mar 23, 2021 08:02AM Akero Therapeutics (AKRO) Announces First Patient Randomized for Dosing in Phase 2b Study of Efruxifermin in F2/F3 NASH Patients
Mar 23, 2021 08:00AM
Mar 23, 2021 08:00AM
Mar 22, 2021 04:03PM
Mar 22, 2021 04:01PM
Mar 22, 2021 04:01PM
Mar 16, 2021 08:00AM
Mar 16, 2021 08:00AM Akero Therapeutics Reports Fourth Quarter and Full Year 2020 Financial Results
Nov 12, 2020 04:05PM

322,245 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All